Aneyefor News

(Albany, New York)- 10th Sep 2026 – DelveInsight’s latest report, “Graft Versus Host Disease Market Insights, Epidemiology and Market Forecast – 2036,” provides a comprehensive analysis of the Graft Versus Host Disease (GvHD) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight’s estimates, the GvHD market in the 7MM was valued at approximately USD 2.1 billion in 2025 and is expected to grow at a CAGR of 6.4% during 2026–2036.

The increasing number of hematopoietic stem cell transplantation (HSCT) procedures, rising GvHD patient burden, improved diagnosis and awareness, advancements in targeted immunomodulatory therapies, and the growing pipeline of biologic, cell-based, and microbiome-based approaches are expected to support market growth through 2036.

Key Takeaways from the Graft Versus Host Disease Market

• The 7MM GvHD market was valued at approximately USD 2.1 billion in 2025 and is projected to grow at a 6.4% CAGR during 2026–2036.

• The United States accounted for approximately USD 1.6 billion in GvHD market revenue in 2025, making it the largest market across the 7MM.

• The 7MM reported approximately 52,000 total GvHD cases in 2025, with the patient pool expected to increase through 2036.

• In the United States, there were approximately 4,300 acute GvHD cases in 2025, while five-year prevalent chronic GvHD cases were estimated at approximately 18,500.

• In 2025, the 7MM recorded approximately 7,100 Grade B (II), 1,800 Grade C (III), and 700 Grade D (IV) acute GvHD cases.

• Ruxolitinib (JAKAFI/JAKAVI) led the GvHD market in revenue generation in 2025, followed by REZUROCK.

• The current treatment landscape includes ruxolitinib, ibrutinib, remestemcel-L, belumosudil, and axatilimab-csfr, among other therapies.

• The emerging pipeline includes MaaT013 (XERVYTEG), RGI-2001, CYP-001, and other immunomodulatory, microbiome-based, and cell-based therapies.

• The United States is expected to remain the dominant market, accounting for approximately 77% of the total 7MM GvHD market by 2036.

• Key companies involved in the GvHD market include AbbVie, Johnson & Johnson, Sanofi, Incyte, Syndax Pharmaceuticals, Novartis, Neovii, Mundipharma, Platinum Life Excellence Biotech, Shionogi, JCR Pharmaceuticals, Bristol Myers Squibb, and others.

Keen to know more about the Graft Versus Host Disease Market Report?https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

Key Factors Driving the Graft Versus Host Disease Market

Increasing Number of Transplant Procedures

The growing volume of hematopoietic stem cell and bone marrow transplantation procedures is a major factor contributing to the increasing incidence and patient burden of GvHD. As the number of transplant procedures rises, demand for effective prophylactic and therapeutic interventions is expected to increase correspondingly.

Rising Prevalence of GvHD

Both acute and chronic GvHD continue to represent substantial complications following allogeneic HSCT. The increasing number of diagnosed cases, together with improvements in patient survival following transplantation, is expected to contribute to a growing treatment population through 2036.

Advancements in Targeted Treatment Approaches

The treatment landscape is shifting from conventional immunosuppression toward more targeted approaches. JAK inhibitors, ROCK2 inhibitors, BTK inhibitors, monoclonal antibodies, and cell-based therapies are increasingly shaping the GvHD treatment paradigm.

Strong Pipeline of Emerging Therapies

The GvHD pipeline is expanding with innovative approaches designed to restore immune tolerance, modulate pathogenic immune responses, and address microbiome dysfunction. Therapies such as MaaT013, RGI-2001, and CYP-001 represent different approaches to addressing persistent unmet needs in GvHD management.

Growing Focus on Personalized and Precision Medicine

Increasing understanding of GvHD pathophysiology is encouraging the development of more personalized treatment strategies. Better risk stratification, biomarker research, targeted immune modulation, and individualized treatment approaches could improve disease management and patient outcomes.

Competitive Landscape

The GvHD market comprises established therapies and an expanding pipeline of targeted, biologic, microbiome-based, and cell-based treatments.

Ruxolitinib (JAKAFI/JAKAVI) from Incyte/Novartis is an oral JAK1/2 inhibitor used in steroid-refractory acute and chronic GvHD. Ibrutinib (IMBRUVICA) from AbbVie/Pharmacyclics and Janssen is a BTK inhibitor indicated for chronic GvHD after failure of prior systemic therapy. Remestemcel-L (RYONCIL/TEMCELL HS) from Mesoblast/JCR Pharmaceuticals is a mesenchymal stromal cell-based therapy for steroid-refractory acute GvHD.

Other important marketed therapies include belumosudil (REZUROCK), a ROCK2 inhibitor, and axatilimab-csfr (NIKTIMVO), a CSF-1R-targeting monoclonal antibody. These therapies demonstrate the shift toward mechanism-specific approaches in GvHD treatment.

Among emerging therapies, MaaT013 (XERVYTEG) from MaaT Pharma is an off-the-shelf pooled-donor microbiome therapy being developed for gastrointestinal-predominant acute GvHD. RGI-2001 from REGiMMUNE is a liposomal alpha-GalCer formulation designed to promote regulatory T-cell activity and immune tolerance, while CYP-001 from Cynata Therapeutics is an immunomodulatory stem cell therapy being evaluated in acute GvHD.

Recent Developments in the Graft Versus Host Disease Market

• May 2026: A new first-in-class therapy for chronic GvHD received regulatory approval in Australia, providing a new treatment option for patients who failed to respond adequately to corticosteroids or other systemic therapies.

• July 2025: MaaT Pharma and Clinigen entered an exclusive long-term licensing, distribution, and commercial supply agreement for MaaT013 for patients with acute GvHD.

• June 2025: MaaT Pharma submitted a marketing authorization application to the EMA for MaaT013 (XERVYTEG), targeting third-line steroid-refractory acute GvHD.

• February 2024: REGiMMUNE reported positive Phase IIb results for RGI-2001 in the prevention of acute GvHD following allogeneic hematopoietic cell transplantation and planned a Phase III randomized study.

• March 2023: REGiMMUNE and San Fu Biotech entered into a licensing agreement to develop and commercialize RGI-2001 for acute GvHD prophylaxis in major Asian markets.

What is Graft Versus Host Disease?

Graft Versus Host Disease is a serious immune-mediated complication that can occur following allogeneic hematopoietic stem cell transplantation. It develops when donor-derived immune cells recognize the recipient’s tissues as foreign and initiate an immune response. The disease most commonly affects the skin, liver, and gastrointestinal tract and can result in significant morbidity and impaired quality of life.

GvHD is broadly classified into acute and chronic forms, with disease severity and organ involvement varying considerably among patients. Diagnosis involves clinical assessment of characteristic signs and symptoms, supported by histopathological evaluation, laboratory testing, and imaging where appropriate.

Current Treatment Landscape

The GvHD treatment landscape has traditionally relied heavily on immunosuppressive therapy and corticosteroids. However, the development of targeted therapies is increasingly changing the treatment paradigm.

Ruxolitinib (JAKAFI/JAKAVI) is a selective JAK1/2 inhibitor that reduces cytokine-driven inflammation and is used for steroid-refractory acute and chronic GvHD. Ibrutinib (IMBRUVICA) inhibits Bruton’s tyrosine kinase and is used in specific chronic GvHD settings. Remestemcel-L represents a cell-based approach with immunomodulatory properties.

For chronic GvHD, belumosudil (REZUROCK) and axatilimab-csfr (NIKTIMVO) provide additional mechanism-specific treatment options. Meanwhile, emerging approaches are increasingly focused on microbiome restoration, immune tolerance, stem-cell-based therapies, and more selective immune modulation.

Despite these advances, significant unmet needs remain, including improved early diagnosis and risk stratification, limited understanding of chronic GvHD pathophysiology, lack of optimized combination therapies, and the need for novel treatments.

Graft Versus Host Disease Epidemiology Segmentation

The GvHD epidemiology analysis covers:

• Total Cases of GvHD

• Type-specific Cases of GvHD

• Acute GvHD Cases by Grading

• Acute GvHD Cases by Organ Involvement

• Chronic GvHD Cases by Grading

• Chronic GvHD Cases by Organ Involvement

• Total Treated Cases of GvHD

• Mortality-adjusted Treated Cases of GvHD

According to DelveInsight, approximately 52,000 total GvHD cases were reported across the 7MM in 2025. In the United States, acute GvHD cases by organ involvement included approximately 3,700 skin cases, 2,100 gastrointestinal cases, and 1,300 liver cases in 2025.

Scope of the Graft Versus Host Disease Market Report

• Study Period: 2022–2036

• Historical Year: 2022–2025

• Forecast Period: 2026–2036

• Base Year: 2025

• Geographies Covered: United States, Germany, France, Italy, Spain, United Kingdom, and Japan

• Market CAGR: 6.4% during 2026–2036

• Market Segmentation: Region/Geographies and Drugs/Therapies

• Epidemiology Segmentation: Total GvHD cases, type-specific cases, acute GvHD cases by grading, acute GvHD cases by organ involvement, chronic GvHD cases by grading, chronic GvHD cases by organ involvement, total treated cases, and mortality-adjusted treated cases

• Key Companies Covered: AbbVie, Johnson & Johnson, Sanofi, Incyte, Syndax Pharmaceuticals, Novartis, Neovii, Mundipharma, Platinum Life Excellence Biotech, Shionogi, JCR Pharmaceuticals, Bristol Myers Squibb, and others

• Key Therapies Covered: Ruxolitinib (JAKAFI/JAKAVI), Ibrutinib (IMBRUVICA), Remestemcel-L (RYONCIL/TEMCELL HS), and others

• Emerging Therapies Covered: MaaT013 (XERVYTEG), RGI-2001, CYP-001, and other pipeline therapies

• Market Analysis: Addressable patient population, market drivers and barriers, cost assumptions and pricing analogues, KOL views, SWOT analysis, reimbursement, conjoint analysis, and unmet needs

• Report Coverage: Disease overview, causes, signs and symptoms, pathogenesis, diagnosis, current and emerging treatments, epidemiology forecasts, historical and forecasted market size, market share by therapies, patient journey, treatment preferences, competitive landscape, and market opportunities across the 7MM.

• Report Insights: GvHD patient population forecast, therapeutics market size, pipeline analysis, market size and trends, and current and forecasted market opportunity

• Key Strengths: Epidemiology-based bottom-up forecasting, AI-enabled market research, 11-year forecast, North America/Europe/Asia-Pacific outlook, disease burden trends, treatment addressable market, competitive landscape, major company insights, drug uptake, and market opportunity assessment.

To know more about the clinical trials, emerging therapies, market landscape, and therapeutic assessment of Graft Versus Host Disease:View the Graft Versus Host Disease Market Report

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Methodology

6. Graft Versus Host Disease Market Overview

7. Disease Background and Overview of Graft Versus Host Disease

8. Diagnosis and Disease Classification

9. Current Treatment Landscape

10. Unmet Needs

11. Epidemiology and Epidemiology Forecast

12. Marketed/Approved Therapies

13. Emerging Therapies

14. Drug Uptake and Market Forecast

15. Market Access and Reimbursement

16. Pricing and Cost Analysis

17. Industry Experts and Physician Views

18. SWOT and Qualitative Analysis

19. Market Drivers and Barriers

20. Competitive Landscape

21. Appendix

22. Methodology

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/